Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...
Brand Name : N115
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 05, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide
Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2020
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?